Browse Category

Financial Insights News 11 November 2025 - 24 November 2025

XPeng Stock (XPEV) on November 24, 2025: Can a 1 Million EV Milestone Offset Cautious Guidance?

XPeng Stock (XPEV) on November 24, 2025: Can a 1 Million EV Milestone Offset Cautious Guidance?

Published: November 24, 2025 – U.S. markets session preview XPeng stock (NYSE: XPEV) heads into the Monday, November 24, 2025 session in a tricky spot: the Chinese EV maker just delivered blowout third‑quarter results, crossed the 1‑million‑vehicle production milestone, and hit its full‑year 2025 sales target two months early—yet the shares have pulled back after management issued a cautious outlook for the fourth quarter. CnEVPost+2CarNewsChina.com+2 Below is a deep dive into where XPeng stands today, what’s driving XPEV’s price action, and the key catalysts investors will be watching as trading resumes. XPeng stock price today: where XPEV stands before the
TSM Stock: 10 Things to Know Before Monday’s Open on November 24, 2025

TSM Stock: 10 Things to Know Before Monday’s Open on November 24, 2025

Taiwan Semiconductor Manufacturing (NYSE: TSM) goes into the new week sitting at the center of the AI chip boom, geopolitical tension, and a fresh round of headlines about trade secrets and export controls. Here’s what traders and long‑term investors should know before the bell on Monday, November 24, 2025. 1. Where TSM Stock Stands Heading Into Monday TSM’s American depositary receipts (ADRs) closed Friday, November 21, at about $275.06, down roughly 0.9% on the day, after trading in a wide intraday range of $266.82 to $278.69. Over the last 52 weeks, the stock has swung between about $134 and $311,
23 November 2025
Canada Goose (GOOS): Fresh 13F Moves, Buyback Launch, and New Analyst Targets — What Investors Need to Know Today (Nov. 11, 2025)

Canada Goose (GOOS): Fresh 13F Moves, Buyback Launch, and New Analyst Targets — What Investors Need to Know Today (Nov. 11, 2025)

What changed today (Nov. 11, 2025) The most recent developments as of Tuesday, Nov. 11 revolve around post‑earnings positioning and new sell‑side targets. Barclays cut its 12‑month price target to $11 while maintaining Equal‑Weight, citing a more cautious view after last week’s results. UBS raised its target to $12 but stayed Neutral, reflecting improving momentum but limited near‑term conviction. GuruFocus+1 Meanwhile, the company’s renewed normal course issuer bid (NCIB) formally began on Nov. 10, enabling buybacks of up to 4.58M shares over the next 12 months—about 10% of the public float—potentially providing a modest support to per‑share metrics during volatility.
11 November 2025

Stock Market Today

Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

7 February 2026
Applied Digital Corporation shares jumped 25.52% Friday to $34.95, then slipped to $34.60 after hours. The company reported fiscal Q2 revenue up 250% to $126.6 million and signed leases for 600 MW of data center capacity in North Dakota. Applied Digital broke ground on a new 430‑MW campus in the southern U.S. in January. Financing includes a $100 million promissory note with 8% interest, paid in kind.
Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

7 February 2026
Eli Lilly shares rose 3.7% to $1,058.18 Friday after the FDA said it would act against telehealth firm Hims & Hers for marketing a $49 compounded weight-loss pill. The move followed a sharp selloff Thursday when Hims announced plans to sell a version of Novo Nordisk’s Wegovy. Investors remain uncertain how aggressively regulators will police copycat drugs and pricing in the obesity drug market.
Go toTop